The vascular effects of cilostazol

Canadian Journal of Cardiology

Volumn 22, Issue SUPPL. B, 2006, Pages 56B-60B

  Weintraub, William S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Platelet inhibition; Restenosis; Vascular biology

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CELL ADHESION MOLECULE; CILOSTAZOL; CLOPIDOGREL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PENTOXIFYLLINE; PLACEBO; PROBUCOL; TICLOPIDINE; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; ARTERY DISEASE; ARTERY INTIMA PROLIFERATION; ATHERECTOMY; ATHEROSCLEROSIS; BLEEDING TIME; BRAIN HEMORRHAGE; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART INFARCTION; HEART PALPITATION; HUMAN; IN-STENT RESTENOSIS; INTERMITTENT CLAUDICATION; LEUKOPENIA; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; REVIEW; SHEAR STRESS; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM;

EID: 33646560707     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0828-282x(06)70987-4     Document Type: Review

References (31)

1. Nakamura T, Houchi H, Minami A, et al. Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta. Life Sci 2001;69:1709-15.
2. Ishizaka N, Taguchi J, Kimura Y, et al. Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis 1999;142:41-6.
3. Ahn CW, Lee HC, Park SW, er al. Decrease in carotid intima. media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2001;52:45-53.
4. Tsuchikane E, Katoh O, Sumitsuji S, et al. Impact of cilostazol on intimal proliferation after directional coronary atherectomy. Am Heart J 1998;135:495-502.
5. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985;35:1144-9.
6. Saitoh S, Saito T, Otake A, et al. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator. Arterioscler Thromb 1993;13:563-70.
7. Igawa T, Tani T, Chijiwa T, et al. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res 1990;57:617-23.
8. Tamai Y, Takami H, Nakahata R, Ono F, Munakata A. Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus. Haemostasis 1999;29:269-76.
9. Nomura S, Shouzu A, Omoto S, et al. Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb Haemost 1998;80:388-92.
10. Tanigawa T, Nishikawa M, Kitai T, et al. Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. Am J Cardiol 2000;85:1054-9.
11. Park SW, Lee CW, Kim HS, et al. Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol 1999;84:511-4.
12. Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing PAD with multiple platelet inhibitors: The effect of combination therapy on bleeding time. J Vasc Surg 2003;38:710-3.
13. Tani T, Uehara K, Sudo T, Marukawa K, Yasuda Y, Kimura Y. Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. Atherosclerosis 2000;152:299-305.
14. Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vase Biol 1998;18:1942-7.
15. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Intern Med 1999;159:2041-50.
16. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109:523-30.
17. Dawson DL, DeMaioribus CA, Hagino RT, et al. The effect of withdrawal of drugs treating intermittent claudication. Am J Surg 1999;178:141-6.
18. Mohler ER III, Beebe HG, Salles-Cuhna S, et al. Effects of cilostazol on resting ankle pressures and exercise, induced ischemia in patients with intermittent claudication. Vase Med 2001;6:151-6.
19. Take S, Matsutani M, Ueda H, et al. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1997;79:1097-9.
20. Yamasaki M, Hara K, Ikari Y, et al. Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation. Cathet Cardiovasc Diagn 1998;44:387-91.
21. Kozuma K, Hara K, Yamasaki M, et al. Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Am Heart J 2001;141:124-30.
22. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999;100:21-6.
23. Park SW, Lee CW, Kim HS, et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol 2000;86:499-503.
24. Sekiya M, Funada J, Watanabe K, Miyagawa M, Akutsu H. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol 1998;82:144-7.
25. Douglas JS, Weintraub WS, Holmes D. Rationale and design of the randomized, multicenter, Cilostazol for RESTenosis (CREST) trial. Clin Cardiol 2003;26:451-4.
26. Douglas JS Jr, Holmes DR, Kereiakes D, et al. Cilostazol for restenosis trial: A randomized, double-blind study following coronary artery scent implantation. American Heart Association Scientific Sessions. Orlando, November 9 to 12, 2003.
27. Serruys PW, de Bruyne B, Carlier S, et al. Randomized comparison of primary stenting and provisional balloon angioplasty guided by flow velocity measurement. Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) II Study Group. Circulation 2000;102:2930-7.
28. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Scent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
29. Stone GW, Ellis SG, Cox DA, et al; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
30. Cutlip DE, Chauhan MS, Baim. DS, et al. Clinical restenosis after coronary stenting: Perspectives from multicenter clinical trials. J Am Coll Cardiol 2002;40:2082-9.
31. Ge J, Han Y, Jiang H, et al; on behalf of the RACTS (A Randomized Prospective Antiplatelet Trial of Cilostazol Versus Ticlopidine in Patients Undergoing Coronary Stenting) Trial Investigators. RACTS: A prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: longterm clinical and angiographic outcome. J Cardiovasc Pharmacol 2005;46:162-6.